Shandong Boan Biotechnology Announces BLA Submission for Two Denosumab Biosimilars in the U.S., Marks Major Global Expansion Milestone
Key Highlights
- Shandong Boan Biotechnology Co., Ltd. (Stock Code: 6955) has submitted Biologics License Applications (BLAs) to the U.S. FDA for two denosumab biosimilars: BA6101 (60 mg) and BA1102 (120 mg).
- Both BA6101 and BA1102 are biosimilars to Amgen’s blockbuster drugs, Prolia® and Xgeva®, respectively.
- The BLA seeks U.S. approval for all indications of the reference drugs: BA6101 targets osteoporosis-related conditions; BA1102 addresses bone metastases, multiple myeloma, giant cell tumor of bone, and hypercalcemia of malignancy.
- Denosumab products generated global sales of approximately US\$6.498 billion in 2025, with US\$4.333 billion from the U.S. alone, underscoring significant market potential.
- Shandong Boan entered an exclusive U.S. commercialization agreement in December 2025 with a leading, unnamed global pharmaceutical partner headquartered in China, which has robust capabilities in R&D, QA, registration, and sales.
- The company is aggressively expanding internationally, with active registration and commercialization efforts in the EU, UK, Japan, Southeast Asia, Latin America, and other high-potential markets.
- Both denosumab biosimilars are already commercially available in China and have received positive feedback from physicians and patients.
- BA6101 also has marketing approval in Bolivia; UK applications are under review.
- Strategic partnerships established for regional launches, including Qingdao Conson Pharmaceutical (Mainland China), Kexing Biopharm (Hong Kong & Macao), Shanghai Pharmaceutical (Southeast Asia), and PHARMACARE (Latin America).
- The company emphasizes ongoing commitment to making high-quality, affordable biologics accessible to patients globally.
Details for Investors and Shareholders
Potentially Price-Sensitive Developments:
- The U.S. BLA submission for two biosimilars is a critical step towards entering the world’s largest pharmaceutical market, which could significantly increase Shandong Boan’s revenue base if approved.
- The exclusive U.S. commercial agreement with a global pharma company enhances the likelihood of a successful market launch and rapid uptake, leveraging established R&D, QA, and distribution channels.
- The current combined market size of Prolia® and Xgeva® in the U.S. alone is over US\$4.3 billion, presenting a substantial commercial opportunity for Boan’s biosimilars.
- Broader international expansion could add multiple new revenue streams, as approvals and launches progress in the UK, EU, Japan, Southeast Asia, and Latin America.
- Strong clinical data supports biosimilarity in safety, efficacy, and purity, positioning the products well for regulatory approvals and physician/patient acceptance.
- Positive feedback and established commercial performance in China de-risk the international launch to some extent.
- The company’s strategy to partner with established pharmaceutical companies in each region is designed to accelerate market penetration and maximize sales potential.
Comprehensive Background
Denosumab is a well-established RANK ligand (RANKL) inhibitor, with over a decade of clinical use and a strong safety and efficacy profile. The reference products, Prolia® and Xgeva®, are recommended in clinical guidelines globally and have demonstrated significant market penetration.
Boan’s BA6101 and BA1102 were independently developed under a global R&D strategy, following strict regulatory pathways outlined in the U.S., EU, UK, Japan, and China. Extensive studies, including pharmaceutical, non-clinical, human pharmacokinetic, and clinical efficacy trials, have confirmed high similarity to the reference products.
Strategic Partnerships and Global Rollout
- China: Qingdao Conson Pharmaceutical (Mainland), Kexing Biopharm (Hong Kong & Macao).
- Southeast Asia: Shanghai Pharmaceutical.
- Latin America: PHARMACARE.
- U.S.: Exclusive agreement with a leading global pharmaceutical company.
These partnerships aim to accelerate commercialization and support robust product launches across multiple territories.
Leadership Endorsement and Board Statement
The announcement is issued by Ms. Jiang Hua, Chairlady, Chief Executive Officer, and Executive Director, who reaffirmed the company’s commitment to improving patient outcomes and delivering high-quality, affordable biologics.
Conclusion
The BLA submissions for BA6101 and BA1102 in the U.S., the exclusive commercial partnership, and the ongoing global expansion efforts constitute potentially transformative news for Shandong Boan Biotechnology. These developments could significantly impact the company’s revenue and share value as they unlock access to multi-billion-dollar markets and establish Boan as a key player in the global biosimilars space.
Disclaimer: This article is based on publicly available company announcements and does not constitute investment advice. Investors should conduct their own research or consult a professional advisor before making investment decisions.
山東博安生物於美國遞交兩款Denosumab生物類似藥BLA，開啟全球擴張新階段
重點摘要
- 山東博安生物股份有限公司（股份代號：6955）已向美國FDA提交兩款Denosumab生物類似藥（BA6101/60mg及BA1102/120mg）的生物製劑許可申請（BLA）。
- BA6101及BA1102分別為安進的暢銷藥Prolia®及Xgeva®的生物類似藥。
- BLA申請覆蓋所有原研藥的適應症：BA6101針對骨質疏鬆相關疾病；BA1102針對實體瘤骨轉移、多發性骨髓瘤、骨巨細胞瘤及惡性高鈣血症。
- 2025年Prolia®及Xgeva®全球銷售額約64.98億美元，美國市場佔43.33億美元，市場潛力巨大。
- 2025年12月與一間總部設於中國的全球知名製藥企業簽訂了美國獨家推廣協議，該夥伴於美國具備強大研發、質控、註冊及銷售能力。
- 積極推進國際市場，包括歐盟、英國、日本、東南亞、拉丁美洲等多地註冊及商業化。
- 兩款Denosumab生物類似藥已於中國上市並獲得醫生及患者正面反饋。
- BA6101已於玻利維亞獲批，英國申請審核中。
- 區域合作網絡包括青島康神（中國內地）、科興生物（港澳）、上海醫藥（東南亞）、PHARMACARE（拉美）。
- 公司強調將持續為全球患者提供高品質、可負擔的生物製劑，提升用藥可及性。
投資者及股東需留意的重要事項
- 美國BLA申請為打入全球最大藥品市場的關鍵步驟，若獲批可大幅提升公司收入。
- 與全球知名藥企合作，有助美國市場推廣、加速商業化及市場接受度。
- 美國市場規模超過43億美元，商業潛力龐大。
- 國際市場註冊進度順利，未來將開啟多重收入來源。
- 臨床數據證明產品安全、純度及有效性高度一致，為監管審批及市場接受度打下基礎。
- 中國市場已成功上市並獲反饋，有助降低國際推廣風險。
- 區域合作策略加速推廣步伐及銷售潛力。
詳細背景
Denosumab為成熟的RANKL抑制劑，擁有超過十年臨床使用經驗，安全有效，並獲多國臨床指南推薦。 博安BA6101及BA1102依據全球監管要求（美、歐、英、日、中）獨立研發，經多項藥學、非臨床、藥代、臨床有效性研究驗證其高度相似性。
全球商業化及戰略合作
- 中國內地：青島康神推廣
- 港澳：科興生物
- 東南亞：上海醫藥
- 拉美：PHARMACARE
- 美國：與全球知名藥企簽訂獨家推廣協議
這些合作將加快全球商業化進度，推動產品迅速進入各大重點市場。
管理層聲明
公告由董事會主席、CEO及執行董事蔣華女士發佈，重申公司致力於提升患者健康，普及高品質、可負擔的生物製劑。
結論
美國BLA申請、全球獨家合作及多地商業化進展，為公司帶來潛在變革性的收入增長前景及提升全球地位，有望對公司股價產生重大正面影響。
免責聲明：本文根據公司公告公開資料編寫，僅供參考，不構成投資建議。投資者請自行研究或諮詢專業顧問後作出投資決策。
